Conclusions
hematological cancers, cancer
CANCER, SECONDARY
Measures of time use, such as contact days, can be extracted from RCTs. In LY.12, despite comparable oncologic outcomes, GDP was associated with fewer contact days. Such information can guide decision-making for patients with hematological cancers, who already face significant healthcare contact.When cancer treatments have similar oncologic outcomes, the number of days with in-person healthcare contact (“contact days’’) can help contextualize expected time use with each treatment. This secondary analysis of the CCTG LY.12 trial analyzed trial forms to assess days with and without health care contact.